DiaSorin have launched three new Primer Pairs for use in molecular testing as part of laboratory developed tests (LDTs).

The Group C Streptococcus, Group G Streptococcus, and Pneumocystis jirovecii Primer Pairs were developed by DiaSorin Molecular LLC in Cypress, California. The addition of these three Primer Pairs contributes to a menu of over 60 molecular reagents that target bacterial, viral, and fungal targets as well as human genetic mutations.

The Group C and G Streptococcus add to the streptococcus product line which also includes Group A Strep and Group B Strep. Group C and G Strep are isolates of streptococci that react with Lancefield group C or G typing serum, respectively. Pneumocystis jirovecii which had previously been classified as Pneumocystis carinii is our first infectious disease fungal target.

“DiaSorin Molecular’s line of molecular reagents for infectious disease testing provides laboratories the ability to develop a robust menu of nucleic acid tests based on the needs of their patient population,” said Michelle Tabb, Vice President of Research and Development, DiaSorin Molecular LLC. “Laboratories are better able to customize assay designs, improve test availability and control costs with access to commercially developed molecular reagents.”

In the US, our Primer Pairs are classified as Analyte Specific Reagents (ASRs) which are utilized by high complexity laboratories in LDTs when an FDA cleared or approved kit might not otherwise be available.

“DiaSorin Molecular continues its commitment to customers in the ongoing design and development of Primer Pairs needed to empower laboratories with accessibility to reagents for molecular assays,” commented Carlo Rosa, Chief Executive Officer of DiaSorin Group. “Our new Primer Pairs, as well as the recently released Simplexa™ C. difficile Direct were selected for development in response to requests from our customers.”